The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease
Abstract
BACKGROUND: We used a sensitive and specific beta-site amyloid precursor protein (APP)-cleaving enzyme 1 (BACE1) assay to determine the relationship between BACE1 activity in cerebrospinal fluid (CSF) and markers of APP metabolism and axonal degeneration in early and late stages of Alzheimer disease (AD). OBJECTIVE: To assess CSF BACE1 activity in AD. DESIGN: Case-control and longitudinal follow-up study. SETTING: Specialized memory clinic. Patients Eighty-seven subjects with AD, 33 cognitively normal control subjects, and 113 subjects with mild cognitive impairment (MCI), who were followed up for 3 to 6 years. MAIN OUTCOME MEASURES: Cerebrospinal fluid BACE1 activity in relation to diagnosis and CSF levels of secreted APP and amyloid beta protein (Abeta) isoforms and the axonal degeneration marker total tau. RESULTS: Subjects with AD had higher CSF BACE1 activity (median, 30 pM [range, 11-96 pM]) than controls (median, 23 pM [range, 8-43 pM]) (P =.02). Subjects with MCI who progressed to AD during the follow-up period had higher baseline BACE1 activity (median, 35 pM [range, 18-71 pM]) than subjects with MCI who remained stable (median, 29 pM [range, 14-83 pM]) (P < .001) and subjects with MCI who developed other forms of dementia (median, 20 pM [range, 10-56 pM]) (P <.001). BACE1 activity correlated positively with CSF levels of secreted APP isoforms and Abeta(40) in the AD and control groups and in all MCI subgroups (P < .05) except the MCI subgroup that developed AD. Strong positive correlations were found between CSF BACE1 activity and total tau levels in all MCI subgroups (r >or= 0.57, P
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“During the past 15 years, a few human in vivo studies reported good diagnostic performance of CSF BACE1 concentration (supposed to reflect gene expression levels) and activity in discriminating among patients with AD dementia, patients with MCI, and cognitively healthy individuals (79–85).”
From The β-Secretase BACE1 in Alzheimer’s Disease (2021) · cites this paper as [83]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
Intracellular amyloid-β in Alzheimer's disease
LaFerla, F. M., Green, K. N., & Oddo, S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2168 · Cited by 1,942
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Roberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705
CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
Strozyk, D., Blennow, K., White, L. R., & Launer, L. J. (2003) · Neurology · doi:10.1212/01.wnl.0000046581.81650.d0 · Cited by 604
β-Secretase Protein and Activity Are Increased in the Neocortex in Alzheimer Disease
Fukumoto, H. (2002) · Archives of Neurology · doi:10.1001/archneur.59.9.1381 · Cited by 575
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 223
Body fluid biomarkers in Alzheimer's disease.
Lu, H., Zhu, X., Jiang, T., Yu, J., & Tan, L. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.02.13 · Cited by 29
Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's disease
Laske, C., Stellos, K., Kempter, I., Stransky, E., Maetzler, W., Fleming, I., & Randriamboavonjy, V. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.06.003 · Cited by 30
Bridging the Gap between Alzheimer’s Disease and Alzheimer’s-like Diseases in Animals
Gołaszewska, A., Bik, W., Motyl, T., & Orzechowski, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071664 · Cited by 31
Syeda, T., & Cannon, J. R. (2021) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.22694 · Cited by 30
Alzheimer's disease biomarkers: correspondence between human studies and animal models
Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27
Mulugeta, E., Londos, E., Hansson, O., Ballard, C. G., Skogseth, R. E., Minthon, L., Blennow, K., Zetterberg, H., & Aarsland, D. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/495025 · Cited by 27
Heteromers of amyloid precursor protein in cerebrospinal fluid
Cuchillo‐Ibáñez, I., López‐Font, I., Boix-Amorós, A., Brinkmalm, G., Blennow, K., Molinuevo, J. L., & Sáez‐Valero, J. (2015) · Molecular Neurodegeneration · doi:10.1186/1750-1326-10-2 · Cited by 27
Savage, M. J., Holder, D., Wu, G., Kaplow, J. M., Siuciak, J. A., & Potter, W. Z. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142778 · Cited by 28
Cerebrospinal Fluid BACE1 Activity and sAβPPβ as Biomarker Candidates of Alzheimer’s Disease
Alexopoulos, P., Thierjung, N., Grimmer, T., Ortner, M., Εconomou, P., Assimakopoulos, K., Gourzis, P., Politis, A. M., Perneczky, R., & Initiative, T. A. D. N. (2018) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000488481 · Cited by 27
An overview of biomarkers in Alzheimer′s disease
Mathuranath, P. S., & Wattamwar, P. R. (2010) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.74256 · Cited by 28
Hassan, M., Abbas, Q., Seo, S., Shahzadi, S., Alashwal, H., Zaki, N., Iqbal, Z., & Moustafa, A. A. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9044 · Cited by 24
Johannsen, J., Weiss, D., Daubmann, A., Schmitz, L., & Denecke, J. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16802 · Cited by 24
Laiterä, T., Kurki, M., Pursiheimo, J., Zetterberg, H., Helisalmi, S., Rauramaa, T. H., Alafuzoff, I. I., Remes, A. M., Soininen, H. S., Haapasalo, A., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150268 · Cited by 24
Araki, W., Hattori, K., Kanemaru, K., Yokoi, Y., Omachi, Y., Takano, H., Sakata, M., Yoshida, S., Tsukamoto, T., Murata, M., et al. (2017) · Biomarker Research · doi:10.1186/s40364-017-0108-5 · Cited by 24
Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer’s disease
Zhang, L., Liang, X., Zhang, Z., & Luo, H. (2021) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545822300014 · Cited by 24
Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment and Dementia
Sonnen, J. A., Montine, K. S., Quinn, J. F., Breitner, J. C. S., & Montine, T. J. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1236 · Cited by 24
Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease
Rosén, C., & Zetterberg, H. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835f6747 · Cited by 23
Insight into the Molecular Imaging of Alzheimer’s Disease
Arora, A., & Bhagat, N. (2016) · International Journal of Biomedical Imaging · doi:10.1155/2016/7462014 · Cited by 23
Alexopoulos, P., Guo, L., Tsolakidou, A. F., Kratzer, M., Grimmer, T., Westerteicher, C., Jiang, M., Bujo, H., Diehl‐Schmid, J., Kurz, A., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110983 · Cited by 23
Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study
Jonsson, M., Zetterberg, H., Rolstad, S., Edman, A., Gouw, A. A., Bjerke, M., Lind, K., Blennow, K., Pantoni, L., Inzitari, D., et al. (2012) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000341576 · Cited by 22
Zetterberg, H., Lautner, R., Skillbäck, T. B., Rosén, C., Shahim, P., Mattsson, N., & Blennow, K. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800141-7.00005-x · Cited by 21
Cerebrospinal fluid Aβ 42 levels and APP processing pathway genes in Parkinson's disease
Bekris, L. M., Tsuang, D. W., Peskind, E. R., Yu, C., Montine, T. J., Zhang, J., Zabetian, C. P., & Leverenz, J. B. (2015) · Movement Disorders · doi:10.1002/mds.26172 · Cited by 22
Lentivirus-Expressed siRNA Vectors Against Alzheimer Disease
Peng, K. A., & Masliah, E. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-533-0_15 · Cited by 22
Vergallo, A., Lemercier, P., Cavedo, E., Lista, S., Vanmechelen, E., Vos, A. D., Zetterberg, H., Blennow, K., Habert, M., Potier, M., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12228 · Cited by 21
Adampourezare, M., Hasanzadeh, M., & Nikzad, B. (2023) · Microchemical Journal · doi:10.1016/j.microc.2023.108931 · Cited by 21
The "Alzheimer's disease signature": potential perspectives for novel biomarkers
Davinelli, S., Intrieri, M., Russo, C., Costanzo, A. D., Zella, D., Bosco, P., & Scapagnini, G. (2011) · Immunity & Ageing · doi:10.1186/1742-4933-8-7 · Cited by 22
Brinkmalm, A., Portelius, E., Brinkmalm, G., Pannee, J., Dahlén, R., Gobom, J., Blennow, K., & Zetterberg, H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14594 · Cited by 23
Blood-based Biomarkers of Alzheimer’s Disease: The Long and Winding Road
Manzine, P. R., Vatanabe, I. P., Peron, R., Grigoli, M. M., Pedroso, R. V., Nascimento, C. M. C., & Cominetti, M. R. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200114105515 · Cited by 22
van Doorn, L. J. C. V. W., Simmelink, M. J. A., Haußmann, U., Klafki, H., Struyfs, H., Linning, P., Knölker, H., Twaalfhoven, H. A. M., Kuiperij, H. B., Engelborghs, S., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13527 · Cited by 20
Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain
Mattsson, N., Johansson, P., Hansson, O., Wallin, A., Johansson, J.-O., Andréasson, U., Andersen, O., Haghighi, S., Olsson, M., Stridsberg, M., et al. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091651 · Cited by 20
Neurochemical biomarkers in Alzheimer’s disease and related disorders
Bibl, M., Esselmann, H., & Wiltfang, J. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612455367 · Cited by 23
Fernström, E., Minta, K., Andréasson, U., Sandelius, Å., Wasling, P., Brinkmalm, A., Höglund, K., Blennow, K., Nyman, J., Zetterberg, H., et al. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12763 · Cited by 22
Genome-wide association study identified ATP6V1H locus influencing cerebrospinal fluid BACE activity
Initiative, A. D. N., Hu, H., Li, H., Li, J., Yu, J., & Tan, L. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0603-z · Cited by 18
Tsolakidou, A. F., Alexopoulos, P., Guo, L., Grimmer, T., Westerteicher, C., Kratzer, M., Jiang, M., Bujo, H., Roselli, F., Leante, M. R., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.01.015 · Cited by 19
Contributive Role of Hyperglycemia and Hypoglycemia Towards the Development of Alzheimer’s Disease
Chakrabarty, R., Yousuf, S., & Singh, M. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02846-y · Cited by 20
P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
Wesenhagen, K. E. J., Tijms, B. M., Boonkamp, L., Hoede, P. L., Goossens, J., Dewit, N., Scheltens, P., Vanmechelen, E., Visser, P. J., & Teunissen, C. E. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01038-z · Cited by 18
Ulku, I., Leung, R., Herre, F., Walther, L., Shobo, A., Säftig, P., Hancock, M. A., Liebsch, F., & Multhaup, G. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107510 · Cited by 20
Abraham, J.-D., Promé, S., Salvetat, N., Rubrecht, L., Cobo, S., Paty, E. D., Galéa, P., Mathieu‐Dupas, E., Ranaldi, S., Caillava, C., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.58 · Cited by 18
Ba, F., Zhou, Y., Zhou, J., & Chen, X. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03531-w · Cited by 21
Lukkarinen, H., Tesseur, I. C., Pemberton, D. J., van der Ark, P. D., Timmers, M., Slemmon, R., Janssens, L., Streffer, J. R., Nueten, L. V., Bottelbergs, A., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201361 · Cited by 19
Identification of ovalbumin-derived peptides as multi-target inhibitors of AChE, BChE and BACE1.
Yu, Z.-P., Dong, W., Wu, S.-J., Shen, J., Zhao, W.-Z., Ding, L., Liu, J.-B., & Zheng, F.-P. (2020) · The Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.10295 · Cited by 16
Lipid flippase dysfunction as a therapeutic target for endosomal anomalies in Alzheimer’s disease
Kaneshiro, N., Komai, M., Imaoka, R., Ikeda, A., Kamikubo, Y., Saito, T., Saido, T. C., Tomita, T., Hashimoto, T., Iwatsubo, T., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103869 · Cited by 16
“Advances in biomarker discovery and diagnostics for alzheimer’s disease”
Bhatia, V., Chandel, A., Minhas, Y., & Kushawaha, S. K. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08023-y · Cited by 21
Development of a specific ELISA to measure BACE1 levels in human tissues
Gonzales, A., Decourt, B., Walker, A. W., Condjella, R. M., Nural, H. F., & Sabbagh, M. N. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2011.08.030 · Cited by 16
Ruan, Q., D’Onofrio, G., Sancarlo, D., Greco, A., & Yu, Z. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5618 · Cited by 18
Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer’s Disease
López‐Font, I., Cuchillo‐Ibáñez, I., Sogorb‐Esteve, A., García‐Ayllón, M., & Sáez‐Valero, J. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00125 · Cited by 16
Manzine, P. R., Souza, M. S., & Cominetti, M. R. (2016) · Personalized Medicine · doi:10.2217/pme-2016-0033 · Cited by 16
New Perspectives for the Diagnosis of Alzheimers Disease
Urbanelli, L., Magini, A., Ciccarone, V. A., Trivelli, F., Polidoro, M., Tancini, B., & Emiliani, C. (2009) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488909789104839 · Cited by 17
Alzheimer’s disease: Pathophysiology and dental pulp stem cells therapeutic prospects
Xiong, W., Liu, Y., Zhou, H., Jing, S., He, Y., & Ye, Q. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.999024 · Cited by 15
Lehmann, S., Schraen‐Maschke, S., Buée, L., Vidal, J., Delaby, C., Hirtz, C., Blanc, F., Paquet, C., Allinquant, B., Bombois, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00755-3 · Cited by 15
Liang, R. F., Li, W. Q., Wang, H., Wang, J. X., & Niu, Q. L. (2013) · PubMed · doi:10.3967/0895-3988.2013.06.005 · Cited by 14
Babylon, L., Schmitt, F., Franke, Y., Hubert, T., & Eckert, G. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158670 · Cited by 12
Protein-Based Biomarkers in Cerebrospinal Fluid and Blood for Alzheimer’s Disease
Fu, Y., Zhao, D., & Yang, L. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0356-x · Cited by 13
Wang, Y., Sørensen, M. G., Zheng, Q., Zhang, C., Karsdal, M. A., & Henriksen, K. (2012) · International Journal of Alzheimer s Disease · doi:10.1155/2012/209409 · Cited by 13
Role of CSF Biomarkers in the Diagnosis of Prodromal Alzheimer‘s Disease
Parnetti, L., & Chiasserini, D. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.48 · Cited by 12
A Common BACE1 Polymorphism Is a Risk Factor for Sporadic Creutzfeldt-Jakob Disease
Calero, O., Bullido, M. J., Clarimón, J., Frank, A., Martínez‐Martín, P., Lleó, A., Rey, M. J., Sastre, I., Rábano, A., de Pedro‐Cuesta, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043926 · Cited by 13
Brain Lipids in the Pathophysiology and Treatment of Alzheimer’s Disease
Torres, M., Busquets, X., & Escribá, P. V. (2016) · InTech eBooks · doi:10.5772/64757 · Cited by 14
Saraceno, C., Cervellati, C., Trentini, A., Crescenti, D., Longobardi, A., Geviti, A., Bonfiglio, N. S., Bellini, S., Nicsanu, R., Fostinelli, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158354 · Cited by 11
BACE1 as an early biomarker and its relevance to risk factors for Alzheimer’s disease
Ohno, M. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111475 · Cited by 12
Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease
Léger, G. C., & Massoud, F. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.811237 · Cited by 10
Hesse, R., von Einem, B., Wagner, F., Bott, P., Schwanzar, D., Jackson, R. J., Föhr, K. J., Lausser, L. M., Kroker, K. S., Proepper, C., et al. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.02.010 · Cited by 10
The Effects of Gene Mutations on Default Mode Network in Familial Alzheimer’s Disease
Li, X., Westman, E., Þórðardóttir, S., Ståhlbom, A. K., Almkvist, O., Blennow, K., Wahlund, L., & Graff, C. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160730 · Cited by 10
Characterization of Cerebrospinal Fluid BACE1 Species
López‐Font, I., Boix, C. P., Zetterberg, H., Blennow, K., & Sáez‐Valero, J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01677-8 · Cited by 10
Tang, W. X., Wang, Y., Cheng, J., Yao, J. J., Yao, Y., Zhou, Q., & Guan, S. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08561-7 · Cited by 10
Cerebrospinal Fluid BACE1 Activity and Brain Amyloid Load in Alzheimer's Disease
Grimmer, T., Alexopoulos, P., Tsolakidou, A. F., Guo, L., Henriksen, G., Yousefi, B. H., Förstl, H., Sorg, C., Kurz, A., Drzezga, A. E., et al. (2012) · The Scientific World JOURNAL · doi:10.1100/2012/712048 · Cited by 10
N-truncated Aβ peptides in complex fluids unraveled by new specific immunoassays
Ranaldi, S., Caillava, C., Promé, S., Rubrecht, L., Cobo, S., Salvetat, N., Paty, E. D., Galéa, P., Aldrian, G., Le‐Nguyen, D., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.05.016 · Cited by 10
Nordberg, A. K., Kadir, A., Andreasen, N., Almkvist, O., Wall, A. E., Blennow, K., Långström, B., & Zetterberg, H. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-132474 · Cited by 9
Faldu, K. G., & Shah, J. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2104639 · Cited by 10
Biofluid biomarkers for Alzheimer’s disease
Wang, S., Xie, S., Zheng, Q., Zhang, Z., Wang, T., & Zhang, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380237 · Cited by 9
Saadaldeen, M., Jeppsson, A., Hellström, P., Blennow, K., Zetterberg, H., Wikkelsø, C., & Tullberg, M. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00661-w · Cited by 8
Araki, W., Kanemaru, K., Hattori, K., Tsukamoto, T., Saito, Y., Yoshida, S., Takano, H., Sakata, M., Yokoi, Y., Omachi, Y., et al. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01935-7 · Cited by 8
Cervellati, C., Vergallo, A., Trentini, A., Campo, G. C., Sega, F. V. D., Rizzo, P., Bonaccorsi, G., Rosta, V., Renzini, C., Pacifico, S., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.78 · Cited by 8
Guo, Y., Hu, Z., & Wang, Z. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.778955 · Cited by 8
Update on amyloid‐βhomeostasis markers for sporadic Alzheimer's disease
Zetterberg, H. (2009) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365510802651841 · Cited by 8
Kühle, J., & Petzold, A. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.592184 · Cited by 8
Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects
Millard, S. P., Lutz, F., Li, G., Galasko, D. R., Farlow, M. R., Quinn, J. F., Kaye, J. A., Leverenz, J. B., Tsuang, D. W., Yu, C., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.07.027 · Cited by 8
Biological Mechanism-based Neurology and Psychiatry: A BACE1/2 and Downstream Pathway Model
Hampel, H. J., Lista, S., Caruso, G., Nisticò, R., Piccioni, G., Mercuri, N. B., Giorgi, F. S., Ferrarelli, F., Lemercier, P., Caraci, F., et al. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211201095701 · Cited by 6
Sjölander, A., Zetterberg, H., Andréasson, U., Minthon, L., & Blennow, K. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-37 · Cited by 6
Gao, F., Zhang, M., Wang, Q., Ni, M., Liu, C., Deng, K., Xie, Q., Wang, S., Shi, J., & Shen, Y. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02750-w · Cited by 4
López‐Font, I., Boix, C. P., Zetterberg, H., Blennow, K., & Sáez‐Valero, J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161275 · Cited by 4
Zakaria, J. A. D., Bateman, R. J., Lysakowska, M., Khatri, A. W., Jean-Gilles, D., Kennedy, M. E., & Vassar, R. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-18869-3 · Cited by 3
Molecular Regulaion of BACE1 and Its Function at The Early Onset of Alzheimer′s Disease
Wang, T., & Sun, X. (2012) · PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS · doi:10.3724/sp.j.1206.2012.00217 · Cited by 3
Araki, W., Araki, Y. M., & Mizusawa, H. (2018) · Neurology and Clinical Neuroscience · doi:10.1111/ncn3.12195 · Cited by 3
Alzheimer’s Disease and Other Neurodegenerative Disorders
Rosén, C., Zetterberg, H., & Blennow, K. (2015) · Springer eBooks · doi:10.1007/978-3-319-01225-4_20 · Cited by 2
Cerebrospinal fluid biomarkers for neurodegenerative disorders
Videira, R. M. A. S. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 2
Fluid Biomarkers in Alzheimer’s Disease and Frontotemporal Dementia
Mattsson, N., Grigoriou, S., & Zetterberg, H. (2018) · Springer eBooks · doi:10.1007/978-3-319-72938-1_11 · Cited by 2
Soluble Amyloid Precursor Proteins in Blood: Methods and Challenges
Perneczky, R., & Alexopoulos, P. (2018) · Neuromethods · doi:10.1007/978-1-4939-7674-4_12 · Cited by 2
Tomasselli, A. G., & Bienkowski, M. J. (2010) · doi:10.1002/9780470594087.ch3 · Cited by 2
Biomarkers for Alzheimer's Disease
Panwar, D., Sharma, P., Sharma, S., Malik, M., & Kaur, J. (2024) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/979-8-3693-6442-0.ch003 · Cited by 1
Kooshki, A., Yousefi, M., Farmani, R., Kabiri-Rad, H., Nezami, H., Zardast, A., & Saremi, Z. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328311 · Cited by 1
Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia
Leyhe, T., Darreh‐Shori, T., Laske, C., Mielke, M. M., & Maetzler, W. (2013) · International Journal of Alzheimer s Disease · doi:10.1155/2013/473181 · Cited by 1
Mining disease associated biomarker networks from PubMed
Huang, Z. (2013) · IEEE International Conference on Systems Biology · doi:10.1109/isb.2013.6623786 · Cited by 1
Laske, C., Stellos, K., Kempter, I., Stransky, E., Maetzler, W., Fleming, I., & Randriamboavonjy, V. (2014) · Cited by 1
Frontiers in Clinical Drug Research - Alzheimer Disorders
Atta-ur-rahman, Mavoungou, C., Zimmerman, K. S., Wright, J., Harding, J., Cavallaro, R., Fuso, A., Yoshiyama, Y., Asija, Z., Clifford, A., et al. (2015) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/97816810806801150301 · Cited by 1
Yin, W.-W., Li, Z., Zheng, W., Zhou, X., Wan, K., Tang, Y., Cao, J., Zhao, H., Zhu, X., & Sun, Z. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01953-2 · Cited by 1
Biomarkers and Alzheimer spectrum
Takeda, M. (2011) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2011.02197.x · Cited by 1
Doppen, P. (2007) · Utrecht University Repository (Utrecht University) · Cited by 1
Guardia‐Laguarta, C. (2010) · TDX (Tesis Doctorals en Xarxa)
New Frontiers in Alzheimer's Disease Diagnosis
Llorens, F., Nuhn, S., Peter, C., Zerr, I., & Stoeck, K. (2015) · InTech eBooks · doi:10.5772/59652 · Cited by 1
Metadata
- Authors
- Zetterberg, H., Andreasson, U., Hansson, O., Wu, G., Sankaranarayanan, S., Andersson, M. E., Buchhave, P., Londos, E., Umek, R. M., Minthon, L., Simon, A. J., & Blennow, K.
- Affiliations
- University of Gothenburg (SE)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2008-08-01
- Volume
- 65
- Issue
- 8
- Pages
- 1102-7
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2117635180
- Cited by
- 224
- References
- 23
- Citations by year
- 2025: 4 · 2024: 8 · 2023: 6 · 2022: 12 · 2021: 11 · 2020: 9 · 2019: 11 · 2018: 18 · 2017: 7 · 2016: 10 · 2015: 20 · 2014: 15 · 2013: 26 · 2012: 21
- FWCI
- 10.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- cerebrospinal fluid, Alzheimer's disease, mild cognitive impairment, amyloid precursor protein, amyloid-beta, total tau, axonal degeneration, APP metabolism, biomarkers, disease progression
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Axons, Enzyme Activation, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Nerve Degeneration, Biomarkers, Case-Control Studies, Aspartic Acid Endopeptidases, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review